Nancy T. RectorApr 8, 20191 min readFDA approves first two-drug complete regimen for HIV-infected patients who have never received anti retrovirus treatment. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm635526.htm?utm_campaign=040919_PR_FDA%20approves%20first%20two-drug%20complete%20regimen%20for%20HIV-infected%20patients&utm_medium=email&utm_source=Eloqua
who have never received anti retrovirus treatment. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm635526.htm?utm_campaign=040919_PR_FDA%20approves%20first%20two-drug%20complete%20regimen%20for%20HIV-infected%20patients&utm_medium=email&utm_source=Eloqua
Johns Hopkins research focused on early stage bladder cancer wins $3.2 million federal grant The new grant will support efforts by Johns Hopkins physician-scientists to participate in a novel multidisciplinary clinical trial for this cancer, called ADAPT-BLADDER for its ability to accomm
FDA approves new treatment for hospital-acquired and ventilator-associated bacterial pneumoniaThe U.S. Food and Drug Administration today approved a new indication for the previously FDA-approved drug, Zerbaxa (ceftolozane and tazob